Abstract
We investigated the treatment outcomes in 88 patients with hypopharyngeal squamous cell carcinoma （HPSCC） treated with transoral laser microsurgery （TLM） and 53 patients with locally advanced laryngeal squamous cell carcinoma （LALSCC） treated with selective radiotherapy and concomitant intra-arterial cisplatin （RADPLAT） from 2001 to 2017. Based on the tumor–node–metastasis （TNM） staging, the HPSCC patients were classified into seven groups: Tis （n＝24）, T1 （n＝27）, T2 （n＝30）, T3 （n＝7）, N0 （n＝73）, N1 （n＝5）, and N2a-b （n＝10）. Likewise, the LALSCC patients were classified into the following seven groups: T2 （n＝10）, T3 （n＝39）, T4a （n＝4）, N0 （n＝44）, N1 （n＝1）, N2b （n＝5）, and N2c （n＝3）. The 5-year local control, disease-specific survival （DSS）, and overall survival （OS） rates of the patients with HPSCC were 81.0%, 92.8%, and 76.2%, respectively, while the 5-year laryngectomy-free survival （LFS） and laryngo-esophageal dysfunction free survival （LEDFS） rates were 75.2% and 62.5%, respectively. The 5-year locoregional control, DSS, and OS of patients with LALSCC were 84.5%, 86.7%, and 81.6%, respectively, while the 5-year LFS and LEDFS rates were 78.7% and 76.6%, respectively. None of the patients presented with a pharyngeal fistula or persistent dysphagia after the TLM. The incidence rates of grade 3 or 4 tumors in patients who received RADPLAT were much lower than those reported previously. TLM and RADPLAT are feasible and safe for laryngeal preservation.
